Model for SorCS1-mediated Diabetes with Dementia

SorCS1 介导的糖尿病伴痴呆模型

基本信息

项目摘要

SUMMARY Type 2 diabetes mellitus (T2D or T2DM) increases the risk for Alzheimer's disease (AD), and SORCS1 is genetically linked to both T2D and AD. We have undertaken a study of the possible role(s) for SorCS1 in metabolism of the Alzheimer's amyloid-¿ (¿¿) precursor protein (APP), in order to define the molecular mechanisms underlying this coordinate genetic linkage to both diseases. Overexpression of SorCS1c¿-myc in cultured cells caused a reduction (p=0.002) in ¿¿ generation (Lane et al., 2010). Endogenous murine A¿40 and ¿¿42 levels were increased (A¿40, p=0.044; A¿42, p=0.007) in the brains of female Sorcs1 hypomorphic mice, possibly paralleling the sexual dimorphism that is characteristic of the genetic associations of SORCS1 with AD and DM. Since SorL1, another AD-linked Vps10-domain protein, directly interacts with Vps35 to modulate APP metabolism, we investigated the possibility that SorCS1c¿-myc might interact with APP, SorL1, and/or Vps35. We readily recovered SorCS1:APP, SorCS1:SorL1, and SorCS1:Vps35 complexes from nontransgenic mouse brain. Notably, total Vps35 protein levels were decreased by 49% (p=0.009) and total SorL1 protein levels were decreased by 29% (p=0.003) in the brains of female Sorcs1-/- mice. We hypothesize that dysfunction of SorCS1 may contribute to both the APP/¿¿ disturbance underlying AD and the insulin/glucose metabolism disturbance underlying DM. In order to test this hypothesis further, we propose the following specific aims: Specific Aim 1. To evaluate the importance of SorCS1 protein interaction motifs and SorCS1/SorL1/APP complex formation on APP metabolism by: (a) Characterizing APP metabolism in cultured cells overexpressing SorCS1; (b) Testing the effects of mutations of protein-protein interacting motifs in the cytoplasmic and ectodomains of SorCS1 on both the formation of tripartite SorCS1/SorL1/APP complexes and APP metabolism; (c) Testing the effect of a putative pathogenic SorCS1 polymorphism on both the formation of tripartite SorCS1/SorL1/APP complexes and APP metabolism; (d) Confirming the importance of functional domains identified in Aim 1aii and 1aiii by viral gene transfer into primary cultures. Specific Aim 2. To employ Sorcs1 hypomorphic and plaque- forming human Swedish APP/PS bigenic mice crossed with Sorcs1 hypomorphic mice for characterization of: (i) endogenous APP metabolism; (ii) hippocampal morphometry, dendritic arborization, and spine structure; (c) learning behavior. Aging (3 mo, 6 mo, 12 mo) effects will also be studied. Specific Aim 3. To perform standard glucose and insulin tolerance tests and metabolic profile phenotyping of Sorcs1-/- mice and plaque-forming" human Swedish APP/PS co-transgenic mice crossed with Sorcs1 -/- mice.
概括 2型糖尿病(T2D或T2DM)增加了阿尔茨海默氏病(AD)的风险,而Sorcs1为 遗传与T2D和AD相关。我们已经研究了Sorcs1可能作用的研究 为了定义分子,阿尔茨海默氏症淀粉样蛋白(APP)的代谢 将这种坐标为两种疾病的遗传联系的机制。 sorcs1c¿-myc的过表达 在培养的细胞中,引起了»生成(Lane等,2010)的降低(P = 0.002)。内源鼠 a¿40和€€增加了42个级别(a¿40,p = 0.044;a¿42,p = 0.007)女性sorcs1 型型小鼠,可能与遗传特征的性二态性平行 Sorcs1与AD和DM的关联。自SORL1(另一种广告连接的VPS10域蛋白)以来,直接 与VPS35相互作用以调节APP代谢,我们研究了Sorcs1c¿-myc可能的可能性 与应用程序,SORL1和/或VPS35进行交互。我们很容易恢复sorcs1:app,sorcs1:sorl1和 SORCS1:来自非转基因小鼠大脑的VPS35复合物。值得注意的是,总VPS35蛋白水平为 在大脑中,降低49%(P = 0.009),总Sorl1蛋白水平降低29%(P = 0.003) 雌性sorcs1 - / - 小鼠的。我们假设SORCS1的功能障碍可能有助于应用程序/�` DM的胰岛素/葡萄糖代谢障碍的障碍和胰岛素/葡萄糖代谢障碍。为了测试 该假设进一步提出了以下特定目的:特定目的1。评估重要性 Sorcs1蛋白相互作用基序和Sorcs1/Sorl1/App复合形成在APP代谢上作者:(a) 表征过表达Sorcs1的培养细胞中的应用代谢; (b)测试 蛋白质 - 蛋白质相互作用基序的突变在两种质质和sorcs1的胞外域的突变 三方Sorcs1/sorl1/应用复合物和应用代谢的形成; (c)测试a的效果 在三方Sorcs1/Sorl1/App Complexs的形成上,假定的致病性Sorcs1多态性 和应用代谢; (d)确认在AIM 1AII和1AIII中确定的功能域的重要性 病毒基因转移到原发性培养物中。特定目的2。对员工Sorcs1 hydormforic和Plaque- 形成与Sorcs1型型型肌big鼠的人类瑞典应用/PS临界小鼠进行表征 的:(i)内源性应用代谢; (ii)海马形态计量学,树突状树博和脊柱 结构; (c)学习行为。衰老(3 mo,6 mo,12个月)的效果也将研究。特定目标3。 执行标准的葡萄糖和胰岛素耐受性测试以及Sorcs1 - / - 小鼠的代谢表型 和形成斑块的“人类瑞典应用程序/PS的共转基因小鼠与Sorcs1 - / - 小鼠交叉。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SAMUEL E. GANDY其他文献

SAMUEL E. GANDY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SAMUEL E. GANDY', 18)}}的其他基金

Proneurogenic Treatment for Amyloid or Tau-Based Neurodegeneration
针对淀粉样蛋白或 Tau 神经变性的促神经源性治疗
  • 批准号:
    10378457
  • 财政年份:
    2017
  • 资助金额:
    $ 36.71万
  • 项目类别:
Proneurogenic Treatment for Amyloid or Tau-Based Neurodegeneration
针对淀粉样蛋白或 Tau 神经变性的促神经源性治疗
  • 批准号:
    9911993
  • 财政年份:
    2017
  • 资助金额:
    $ 36.71万
  • 项目类别:
Rehab Therapy Adjunct with a Neurogenic, Mnemoactive, A-Beta-Lowering Compound
含有神经源性、记忆活性、A-β 降低化合物的康复治疗辅助剂
  • 批准号:
    9220567
  • 财政年份:
    2014
  • 资助金额:
    $ 36.71万
  • 项目类别:
Rehab Therapy Adjunct with a Neurogenic, Mnemoactive, A-Beta-Lowering Compound
含有神经源性、记忆活性、A-β 降低化合物的康复治疗辅助剂
  • 批准号:
    8596270
  • 财政年份:
    2014
  • 资助金额:
    $ 36.71万
  • 项目类别:
Rehab Therapy Adjunct with a Neurogenic, Mnemoactive, A-Beta-Lowering Compound
含有神经源性、记忆活性、A-β 降低化合物的康复治疗辅助剂
  • 批准号:
    9026594
  • 财政年份:
    2014
  • 资助金额:
    $ 36.71万
  • 项目类别:
Rehab Therapy Adjunct with a Neurogenic, Mnemoactive, A-Beta-Lowering Compound
含有神经源性、记忆活性、A-β 降低化合物的康复治疗辅助剂
  • 批准号:
    8825927
  • 财政年份:
    2014
  • 资助金额:
    $ 36.71万
  • 项目类别:
Generation and Characterization of Alzheimer Brain Cells
阿尔茨海默病脑细胞的生成和表征
  • 批准号:
    8370239
  • 财政年份:
    2012
  • 资助金额:
    $ 36.71万
  • 项目类别:
Model for SorCS1-mediated Diabetes with Dementia
SorCS1 介导的糖尿病伴痴呆模型
  • 批准号:
    8788636
  • 财政年份:
    2012
  • 资助金额:
    $ 36.71万
  • 项目类别:
Model for SorCS1-mediated Diabetes with Dementia
SorCS1 介导的糖尿病伴痴呆模型
  • 批准号:
    8411973
  • 财政年份:
    2012
  • 资助金额:
    $ 36.71万
  • 项目类别:
Model for SorCS1-mediated Diabetes with Dementia
SorCS1 介导的糖尿病伴痴呆模型
  • 批准号:
    8295466
  • 财政年份:
    2012
  • 资助金额:
    $ 36.71万
  • 项目类别:

相似海外基金

Uncovering Mechanisms of Racial Inequalities in ADRD: Psychosocial Risk and Resilience Factors for White Matter Integrity
揭示 ADRD 中种族不平等的机制:心理社会风险和白质完整性的弹性因素
  • 批准号:
    10676358
  • 财政年份:
    2024
  • 资助金额:
    $ 36.71万
  • 项目类别:
The Influence of Lifetime Occupational Experience on Cognitive Trajectories Among Mexican Older Adults
终生职业经历对墨西哥老年人认知轨迹的影响
  • 批准号:
    10748606
  • 财政年份:
    2024
  • 资助金额:
    $ 36.71万
  • 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
  • 批准号:
    10749539
  • 财政年份:
    2024
  • 资助金额:
    $ 36.71万
  • 项目类别:
Individual Predoctoral Fellowship
个人博士前奖学金
  • 批准号:
    10752036
  • 财政年份:
    2024
  • 资助金额:
    $ 36.71万
  • 项目类别:
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
  • 批准号:
    10462257
  • 财政年份:
    2023
  • 资助金额:
    $ 36.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了